Scientific <strong>Poster</strong>s – <strong>Poster</strong> <strong>Session</strong> 2Conclusion: This study demonstrated that the prognosisof chondrosarcoma of extremities and axial bones is relatedwith anatomical location, size of the tumor, pathologicgrade and surgical resection margin.<strong>Poster</strong> #136AVOIDING BIOPSY IN CHONDROID TUMORS:PROSPECTIVE PET-CT GRADING WITH EXCISIONSPECIMEN HISTOLOGICAL CORRELATIONPrakash R. Nayak, MD; Manish G. AgarwalOrthopedic <strong>Oncology</strong>, P.D. Hinduja Hospital, Mumbai, IndiaObjective: To prospectively evaluate role of PET CTgrading and staging of solitary chondroid tumors andHereditary Multiple Exostoses with the aim of avoidinga biopsy.Methods: Retrospective analysis of 45 chondroid lesions,4 patients with hereditary multiple exostoses(39 lesions)and 6 patients with unequivocal clinical and radiologicaldiagnosis of a solitary chondroid neoplasm from 2010 to2012 who underwent PET CT scan as a prospective stagingand grading modality was performed.A standardprotocol 10mCi dosage of FDG 18,followed 30 mins laterwith oral contrast agent trazogastro 10ml/500ml waterwas administered.An hour later PET CT images acquiredand reconstructed to obtain fused,trans-axial,coronal andsagital views of 3.7 mm thickness.SUV max based on ROI,after attentuation correction based on CT images were calculatedfor each lesion.Focal areas of asymmetric uptakewere noted.SUV max was correlated with final histologicalgrade on excision specimen and asymmetric ares werenoted for areas of de-differentiation.Results: All lesions grade 2 and 3 had an SUV averageof 7.5(3.4 to 11,n=4). De differentiated variant had anSUV of 38.4,with a sacral metastatic lesion having SUV10.1.Amongst 39 lesions in the Hereditary Multiple Exostosisgroup, only 3 grade 1 malignancies averaged SUV2.5.None of the lesions clinically silent had an SUVmax of>1.9(n=36).The lesions suspicious for chondrosarcomatouschange in the HME group averaged SUV 2.8(2.3 to 2.9,n=4).A cut off level 3 identified all 11 lesions with chondrosarcomatouschange grade 2 and above.Conclusion: PET CT is an important adjunct to conventionalimaging to stage and grade chondrosarcomas accurately.Thecurrent series although low in numbers tohave statistical significance has been 100 % accurate withan SUV cutoff of 3 for grade 2 and above chondrosarcoma.It has also been able to screen and have specificity in identifyingand grading chondrosarcomatous change in over39 lesions in 4 patients of HME,Although they behavedifferently than long and flat bone chondrosarcomas, theyhave been comparable with SUV pick up rates.They havecorrelated a 100 % with final post excision histology andhelped avoid a pre operative biopsy in all of the abovepatients.This in our knowledge is the first report with nopre surgical biopsy on chondroid lesions with success inthe entire cohort.casenumberagesexfinal histologicalgraderange ofSUVtotal number oflesionsSUV of excisedlesion(target lesion)1 61 male 0 1.3-1.5 13 1.52 30 male 1 2.7-3.4 9 3.43 6 male 0 0.9 to 1.8 8 1.94 16 male 1 1.3-2.8 9 2.85 44 female 2 11.1 1 11.16 52 male 4 10.1,38.4 2 38.47 38 male 2 4.01 1 4.018 34 female 1 7.3 1 7.39 56 male 2 4.4-5.1 2 5.110 38 female 1 2.7 1 2.7234
Scientific <strong>Poster</strong>s – <strong>Poster</strong> <strong>Session</strong> 2<strong>Poster</strong> #137CHONDROSARCOMA OF BONE IN CHILDRENAND ADOLESCENTSPer-Ulf Tunn 1 ; Andreas Frings 2 ; Mathias Werner 3 ;Dimosthenis Andreou 1 ; Andreas Leithner 21Orthopedic <strong>Oncology</strong>, HELIOS-Klinikum Berlin Buch,Sarcoma Center Berlin-Brandenburg, Berlin, Germany;2Department of Orthopedics and Orthopedic Surgery,Medical University of Graz, Graz, Austria; 3 Department ofPathology, HELIOS Klinikum Emil von Behring, SarcomaCenter Berlin-Brandenburg, Berlin, GermanyObjective: Chondrosarcoma of bone rarely affects childrenand adolescents and there are only a few data about itscourse in this subgroup of patients in the literature. Theobjective of this study was to examine the clinical courseand outcome of chondrosarcoma of bone in children andadolescents.Methods: 13 children and adolescents, 9 female and 4 male,with a chondrosarcoma of the pelvis (n=4), the humerus(n=3), the femur (n=2), the phalanges of the hand (n=2), thetibia (n=1) and the thoracic wall (n=1) underwent operativetreatment at our institutions between 1978 and 2011. Meanpatient age at diagnosis amounted to 15.2 years (range, 11– 18 years), mean follow-up was 10.3 years (range, 0.33– 21.25 years).Results: : 8 patients presented with a grade 1, 4 patientswith a grade 2 and 1 patient with a grade 3 tumor. 4 patientsunderwent an intralesional and 9 patients a wideresection, according to the Enneking classification. Nopatients received chemotherapy; adjuvant radiotherapywas performed in 1 patient. 5 patients developed a localrecurrence after a mean of 2.6 years (range, 0.6 – 6.5 years),following an intralesional resection in 3 cases and a wideresection in the remaining 2 patients. All 5 local recurrenceswere treated operatively. 1 patient with a grade 3 tumordeveloped lung metastases 4 years after initial diagnosis,which were also treated operatively. No patient has diedof disease in follow-up.Conclusion: Chondrosarcoma of bone in children andadolescents appears to have an excellent prognosis. Surgicalresection without adjuvant treatment appears to besufficient both for primary and recurrent tumors.<strong>Poster</strong> #138CARBON ION RADIOTHERAPY FORUNRESECTABLE SPINAL AND PARASPINALSARCOMASReiko Imai; Tadashi Kamada; Katsuya MaruyamaResearch Center Hospital for Charged Particle Therapy,National Institute of Radiological Sciences, Inage, JapanObjective: The standard treatment for spinal and paraspinalsarcomas has been en bloc resection. However thosesarcomas involving or close to the spinal canal have beenone of the most challenging for orthopedic surgeons. Dueto the high linear energy transfer (LET) and the Braggpeak, carbon ion radiotherapy has been expected to bemore effective and safe in the treatment for sarcomasthan low-LET radiation like photons. We evaluated theeffectiveness and safety of carbon ion radiotherapy inpatients with spinal and paraspinal sarcoma not suitablefor surgical resection.Methods: Between June 1996 and February 2012, 100cases with spinal and paraspinal sarcomas received carbonion radiotherapy. Ages ranged from 12 to 84 (median 53years). Forty nine spinal and 51 paraspianal sarcomas wereincluded. Fifty nine patients had primary disease presentation,25 patients with recurrent disease after surgery and16 patients with metastases. Pathological types were asfollows: chondrosarcoma in 20, osoteosarcoma in 17, chordomain 12, MFH originated from soft tissue in 10, MPNSTin 5. Carbon ion radiotherapy was delivered in 16 fractionsover 4 weeks. Median total dose was 70.4GyE (range from52.8 to 70.4GyE). Clinical target volumes ranged between12 and 1259 cm3 (median 205 cm3).Results: Median follow up time was 31 (range: 2-162)months for all patients and all living patients were followedmore than 6 months. At 5 years, actuarial overalllocal control (LC) rate and overall survival (OS) rate were75% and 51%, respectively. Twelve patients with spinalsarcoma including 8 high grade sarcomas and 18 patientswith paraspinal sarcoma including 12 high grade sarcomashave survived for 5 years. Two patients experienced grade3 spinal cord late reaction in this series.Conclusion: Carbon ion radiotherapy is suggested to bean effective and safe treatment for spinal and paraspinalsarcoma patients, especially for whom surgical resectionis not a viable option.<strong>Poster</strong> #139HIGH-DOSE PHOTON-BEAM RADIATIONTHERAPY IN CHORDOMA:A SINGLE-INSTITUTION RETROSPECTIVEANALYSISClaudia Sangalli 1 ; Silvia Stacchiotti 2 ; Alessandro Gronchi 3 ;Marzia Franceschini 1 ; Paolo G. Casali 2 ; Emanuele Pignoli 4 ;Elena Palassini 2 ; Marta Barisella 5 ; Riccardo Valdagni 11Radiotherapy, Fondazione IRCCS Istituto Nazionale Tumori,Milano, Italy; 2 Department of Cancer Medicine, FondazioneIRCCS Istituto Nazionale Dei Tumori, Milano, Italy;3Department of Surgery, Fondazione IRCCS IstitutoNazionale Dei Tumori, Milano, Italy; 4 Department of Medical235